TP53 and gastric cancer: In gastric cancer, serum NY-ESO-1 and p53 autoantibodies are associated with postoperative recurrence, with NY-ESO-1 seropositivity at 3 and 12 months after surgery independently predicting shorter recurrence-free survival [17].